Parasitic immunology is a specialized field that explores the interactions between the immune system and parasitic organisms, including protozoa, helminths, and ectoparasites. Parasitic infections affect billions of people worldwide, leading to a diverse range of diseases, from malaria and leishmaniasis to schistosomiasis and intestinal worm infections. The immune response to parasitic infections involves a complex interplay of innate and adaptive immune components. Evasion strategies employed by parasites, such as antigenic variation and modulation of host immune responses, challenge the host's ability to mount effective defenses. Research in parasitic immunology aims to understand the mechanisms of host-parasite interactions, identify key immune effectors, and develop interventions to control parasitic diseases. Vaccination strategies, antiparasitic drugs, and vector control measures are crucial aspects of parasitic immunology research. The immune response to parasites often involves a delicate balance between protective immunity and immunopathology. Unraveling the intricacies of parasitic immunology is essential for developing effective preventive and therapeutic strategies to combat parasitic infections and improve global public health.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States